Dynamic Proteomic and PTMomic Characterization of Mycobacteria after Clinical Pharmaceutical Intervention
文献类型：期刊论文
| 作者 | Yin, Jun2,3; Wang, Liming4; Jin, Hailong5; Zhang, Mingya6,7; Jiang, Tian2,3; Kan, Yunbo1,6; Liu, Tianxian6; Su, Feng2,3; Zhao, Lei8; Li, Yi6 |
| 刊名 | ACS INFECTIOUS DISEASES
 |
| 出版日期 | 2025-08-12 |
| 页码 | 13 |
| 关键词 | mycobacteria
antituberculosis drugs
S/T/Yphosphorylation
lysine acylation
|
| ISSN号 | 2373-8227 |
| DOI | 10.1021/acsinfecdis.4c00891 |
| 英文摘要 | Tuberculosis, a major global health threat, necessitates understanding the pharmacological mechanisms of current drugs to combat multidrug resistance. In addition to alterations at the proteome level, the dynamic changes occurring at various levels of post-translational modifications (PTMs) following pharmacological intervention remain unclear. In our current study, we employed a quantitative proteomic approach to systematically analyze the dynamic molecular alterations at both the proteome and PTM levels in response to clinical drugs, including ethambutol, bedaquiline, moxifloxacin, and streptomycin. Our findings revealed enriched bioprocesses beyond known functions, phosphorylation-level changes in kinases and phosphatases, and increased acetylation levels with all four drugs. Overexpression of CobB in Mycobacterium smegmatis significantly increased its susceptibility to ethambutol, indicating enhanced drug sensitivity. Our study provides integrated multiomics resources for understanding the dynamic molecular characteristics and drug resistance associated with clinical drug interventions and proposes novel therapeutic strategies targeting the PTM levels. |
| WOS关键词 | ANTIMICROBIAL RESISTANCE ; LYSINE ACETYLATION ; TUBERCULOSIS ; SUSCEPTIBILITY ; VIRULENCE ; REVEALS |
| 资助项目 | Sanofi[2021YFA0804700] ; Sanofi[2021YFA0804701] ; Sanofi[2023YFA1800400] ; Sanofi[2023YFA1800403] ; National Key R&D Program of China[32322048] ; National Key R&D Program of China[32471497] ; National Key R&D Program of China[22225702] ; National Key R&D Program of China[31901036] ; National Key R&D Program of China[82241013] ; Natural Science Foundation of China[22QA1411100] ; Shanghai Rising-Star Program[CAS2021276] ; Youth Innovation Promotion Association[2022QNRC001] ; Young Elite Scientists Sponsorship Program by CAST[20ZR1411600] ; Natural Science Foundation of Shanghai[CESS2021TC04] ; Bethune Ethicon Excellent Surgery Foundation[BSZK-2023-A03] ; Baoshan District Health Commission Key Subject Construction Project[CXTD2024006] ; Baoshan District Health Commission Key Subject Construction Project[CXTD2023009] ; Zhongshan Science and Technology Bureau[22XD1420900] ; Program of Shanghai Academic Research Leader[2019B090904008] ; Guangdong High-level New R&D Institute, China[2021B0909050003] ; Guangdong High-Level Innovative Research Institute, China ; Sanofi Scholarship Program |
| WOS研究方向 | Pharmacology & Pharmacy ; Infectious Diseases |
| 语种 | 英语 |
| WOS记录号 | WOS:001548378000001 |
| 出版者 | AMER CHEMICAL SOC |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/321246]  |
| 专题 | 国家级研究中心_原创新药研究全国重点实验室 |
| 通讯作者 | Song, Yuanlin; Tan, Lijie; Xu, Jun-Yu |
| 作者单位 | 1.Jiangsu Ocean Univ, Coll Pharm, Jiangsu Key Lab Marine Pharmaceut Cpd Screening, Lianyungang 222005, Peoples R China 2.Fudan Univ, Dept Thorac Surg, Zhongshan Hosp, Shanghai 200032, Peoples R China 3.Shanghai Resp Res Inst, Shanghai Inst Infect Dis & Biosecur, Shanghai Key Lab Lung Inflammat & Injury, Shanghai 200032, Peoples R China 4.Shanghai Xuhui Cent Hosp, Dept Resp & Crit Care Med, Shanghai 200031, Peoples R China 5.Wusong Cent Hosp, Dept Thorac Surg, Shanghai 200940, Peoples R China 6.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 7.Fudan Univ, Sch Pharm, Dept Med Chem, Shanghai 201203, Peoples R China 8.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Mat Med, Zhongshan 528400, Peoples R China 9.Baoshan Canc Ctr, Shanghai 200940, Peoples R China 10.Fudan Univ, Dept Pulm Med, Zhongshan Hosp, Shanghai 200032, Peoples R China |
| 推荐引用方式 GB/T 7714 | Yin, Jun,Wang, Liming,Jin, Hailong,et al. Dynamic Proteomic and PTMomic Characterization of Mycobacteria after Clinical Pharmaceutical Intervention[J]. ACS INFECTIOUS DISEASES,2025:13. |
| APA | Yin, Jun.,Wang, Liming.,Jin, Hailong.,Zhang, Mingya.,Jiang, Tian.,...&Xu, Jun-Yu.(2025).Dynamic Proteomic and PTMomic Characterization of Mycobacteria after Clinical Pharmaceutical Intervention.ACS INFECTIOUS DISEASES,13. |
| MLA | Yin, Jun,et al."Dynamic Proteomic and PTMomic Characterization of Mycobacteria after Clinical Pharmaceutical Intervention".ACS INFECTIOUS DISEASES (2025):13. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。